公开(公告)号：US11525120B2

公开(公告)日：2022-12-13

申请号：US17472263

申请日：2021-09-10

申请人： Vertex Pharmaceuticals Incorporated

发明人： Felicia J. Pagliuca ,  George Harb ,  Lillian Ye

IPC分类号： C12N5/071

摘要： Provided herein are methods of producing β cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells.

公开(公告)号：US20210403876A1

公开(公告)日：2021-12-30

申请号：US17472263

申请日：2021-09-10

申请人： Vertex Pharmaceuticals Incorporated

发明人： Felicia J. Pagliuca ,  George Harb ,  Lillian Ye

IPC分类号： C12N5/071

摘要： Provided herein are methods of producing β cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells.

公开(公告)号：US11466256B2

公开(公告)日：2022-10-11

申请号：US17472220

申请日：2021-09-10

申请人： Vertex Pharmaceuticals Incorporated

发明人： Felicia J. Pagliuca ,  George Harb ,  Lillian Ye

IPC分类号： C12N5/071

摘要： Provided herein are methods of producing β cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells.

公开(公告)号：US20210403875A1

公开(公告)日：2021-12-30

申请号：US17472220

申请日：2021-09-10

申请人： Vertex Pharmaceuticals Incorporated

发明人： Felicia J. Pagliuca ,  George Harb ,  Lillian Ye

IPC分类号： C12N5/071

摘要： Provided herein are methods of producing β cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells.

公开(公告)号：US11999971B2

公开(公告)日：2024-06-04

申请号：US18055312

申请日：2022-11-14

申请人： Vertex Pharmaceuticals Incorporated

发明人： Felicia J. Pagliuca ,  George Harb ,  Lillian Ye

IPC分类号： A61K35/39 ,  A61P5/50 ,  C12N5/071 ,  A61K35/12

CPC分类号： C12N5/0678 ,  A61K35/39 ,  A61P5/50 ,  A61K2035/126 ,  C12N2500/46 ,  C12N2501/11 ,  C12N2501/117 ,  C12N2501/119 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/19 ,  C12N2501/415 ,  C12N2501/999

摘要： Provided herein are methods of producing β cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells.

公开(公告)号：US20210238553A1

公开(公告)日：2021-08-05

申请号：US17171497

申请日：2021-02-09

申请人： Vertex Pharmaceuticals Incorporated

发明人： Felicia J. Pagliuca ,  George Harb ,  Lillian Ye

IPC分类号： C12N5/071

摘要： Provided herein are methods of producing β cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells.

公开(公告)号：US20210198632A1

公开(公告)日：2021-07-01

申请号：US17010346

申请日：2020-09-02

申请人： Vertex Pharmaceuticals Incorporated

发明人： Felicia Pagliuca ,  George Harb ,  Mads Gurtler ,  Jason Gaglia ,  Yeh-Chuin Poh ,  Lillian Ye ,  Austin Thiel ,  Jihad Yasin ,  Evrett Thompson

IPC分类号： C12N5/071

摘要： Disclosed herein are compositions and methods of enhancing stem cell differentiation into beta cells with use of one or more epigenetic modification compounds. The present disclosure also relates to compositions and methods of sorting and enriching the differentiated beta cells. The present disclosure also relates to compositions and methods of irradiating cell population for reducing proliferation.